The main purpose of this study is to describe how well Guselkumab works after switching from Ustekinumab in participants with moderate to severe psoriasis in a routine clinical setting. A long-term skin disease that causes red, scaly and sometimes painful, itchy patches on the skin.
Inclusion criteria:
Exclusion criteria:
Participate-In-This-Study1@its.jnj.com
Participants with moderate-to-severe psoriasis who are candidates for systemic treatment (according to the guselkumab label) and who are medically indicated to switch from Ustekinumab or its biosimilar to receive Guselkumab in routine clinical practice will be enrolled. No drug will be provided as a part of this study. Only data available from routine clinical practice will be collected.
A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe Psoriasis
A Study of Guselkumab in Participants With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab
Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Active Psoriatic Arthritis (PsA)
A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis
A Study of Guselkumab in Participants With Active Psoriatic Arthritis
A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis
A Study of Guselkumab in Participants With Psoriatic Arthritis (PsA) in a Real-World Setting